Loading
Cancer Genomics and Diagnostics / Cancer Cells and Metastasis / Ovarian Cancer Diagnosis and Treatment · Journal article
BMC Cancer · September 8, 2026
Encouraging direction, but not yet definitive.
This prospective case–control study of 150 participants demonstrates that circulating cell-free DNA (cfDNA) concentrations differ markedly between ovarian cancer, benign ovarian lesions, and healthy controls, with high discriminatory accuracy (AUC 0.934 for cancer detection) and association with late-stage disease and survival outcomes. While the biomarker performance is striking, the study is observational and single-centre, and the clinical value of cfDNA for treatment decision-making remains unproven; independent external validation and prospective management trials are required before adoption in routine practice.
Prospective case–control study. 50 patients with confirmed ovarian cancer, 50 with benign ovarian lesions, and 50 healthy control participants. Specific eligibility criteria, setting, and demographic details not reported.. Intervention: Quantification of circulating cell-free DNA (cfDNA) by real-time PCR.. Compared with: Benign ovarian lesion group and healthy control group.. n = 150.
Mean cfDNA was 11.84 ng/mL in malignant ovarian cancer, 3.90 ng/mL in benign lesions, and 0.23 ng/mL in controls. ROC AUC for ovarian cancer detection was 0.934 (95% CI 0.881–0.986, p < 0.001). ROC AUC for late-stage disease prediction was 0.993 (95% CI 0.978–1.0, p < 0.001).
ROC AUC for mortality prediction was 0.814 (95% CI 0.690–0.937, p = 0.001).
Clinicians should note that cfDNA shows promising discriminatory performance for ovarian cancer and association with survival, but this is a single, modestly sized case–control study. Before implementing cfDNA in clinical risk stratification or treatment planning, independent external validation in prospective cohorts and demonstration of clinical utility over existing biomarkers (e.g., CA-125) are essential.
A prospective case–control study of modest size (150 participants) with clear separation between groups and strong ROC performance for a candidate biomarker, but surrogate endpoints (AUC, survival association) rather than a clinical trial of intervention, requiring confirmation in independent cohorts.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that cfDNA shows promising discriminatory performance for ovarian cancer and association with survival, but this is a single, modestly sized case–control study. Before implementing cfDNA in clinical risk stratification or treatment planning, independent external validation in prospective cohorts and demonstration of clinical utility over existing biomarkers (e.g., CA-125) are essential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Due to a lack of efficient screening methods or trustworthy biomarkers with high sensitivity and specificity, ovarian cancer (OC) is a quarrelsome disease with a high death rate. Investigators believe that circulating tumor cell-free DNA (cfDNA) can provide crucial clues concerning both primary and metastatic OCs. Our goal was to identify the potential of circulating cfDNA as a non-invasive biomarker for ovarian cancer. This case‒control prospective study was carried out on 150 participants, of whom 50 patients were confirmed to have ovarian cancer, 50 patients had benign ovarian lesions, and 50 participants were controls. For OC patients, medical, laboratory, and imaging evaluations together with survival analysis were performed. Quantification of cfDNA was done by real-time PCR. A distinct difference in the mean cfDNA was observed in the malignant group (11.84 ng/mL) compared to the benign (3.90 ng/mL) and control (0.23 ng/mL) groups. ROC curve analysis revealed that cfDNA had the highest value as a strong discriminatory marker for prediction of ovarian cancer in suspected cases and prediction of late stage and is a reasonable predictor of mortality (AUC 0.934, p < 0.001, 95% CI: 0.881–0.986; AUC 0.993, p < 0.001, 95% CI: 0.978–1.0; and AUC 0.814, p = 0.001, 95% CI: 0.690–0.937). The multivariate logistic regression reinforces its independent prognostic value for progression-free survival and overall survival. Our results indicate that cfDNA has a strong correlation with tumor grade and predictive capability in Cox models, suggesting that it may serve as a diagnostic and prognostic biomarker for OC. In clinical setting, these findings support the use of cfDNA in OC risk stratification and treatment planning, potentially enabling aggressive therapies for patients with high cfDNA expression.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.